Neurology 2003;60:652-656
© 2003 American Academy of Neurology
CSF Aß 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D. Strozyk, MD,
K. Blennow, MD PhD,
L. R. White, MD and
L. J. Launer, PhD
From the Laboratory of Epidemiology, Demography and Biometry (Drs. Strozyk and Launer), National Institute on Aging, NIH, Bethesda, MD; Department of Clinical Neuroscience (Dr. Blennow), Sahlgren’s University Hospital, Mölndal, Sweden; and Pacific Health Research Institute (Dr. White), Honolulu, HI.
Address correspondence and reprint requests to Dr. D. Strozyk, LEDB/NIA/NIH, Gateway Bldg 3C-309, 7201 Wisconsin Avenue, Bethesda, MD 20892; e-mail: strozykd{at}mail.nih.gov
Objective: To investigate the relationship of amyloid neuropathology to postmortem CSF Aß 42 levels in an autopsy sample of Japanese American men from the population-based Honolulu–Asia Aging Study.
Methods: In 1991, participants were assessed and diagnosed with dementia (including subtype) based on published criteria. At death CSF was obtained from the ventricles. Neuritic plaques (NP) and diffuse plaques in areas of the neocortex and hippocampus were examined using Bielschowsky silver stains. Cerebral amyloid angiopathy (CAA) was measured by immunostaining for ß4 amyloid in cerebral vessels in the neocortex. Neuropathologically confirmed AD was diagnosed using Consortium to Establish a Registry for Alzheimer’s Disease criteria. In 155 autopsy samples, log transformed linear regression models were used to examine the association of NP and CAA to Aß 42 levels, controlling for clinical dementia severity, time between diagnosis and death, age at death, brain weight, hours between death and collection of CSF, education, and APOE genotype.
Results: Higher numbers of NP in the neocortex (p trend = 0.001) and in the hippocampus (p trend = 0.03) were strongly associated with lower levels of Aß 42. Individuals with CAA had lower Aß 42 levels (ß coefficient = -0.48; 95% CI -0.9, -0.1). Compared to participants with a diagnosis of clinical dementia, those with pathologically confirmed AD had lower Aß 42 levels (ß coefficient = -0.74; 95% CI -1.4, -0.1).
Conclusion: The current study suggests that lower Aß 42 levels reflect neuropathologic processes implicated in amyloid-related pathologies, such as NP and CAA.
This article has been cited by other articles:
|
|
|
|
 
A. M. Fjell, K. B. Walhovd, C. Fennema-Notestine, L. K. McEvoy, D. J. Hagler, D. Holland, K. Blennow, J. B. Brewer, A. M. Dale, and the Alzheimer's Disease Neuroimaging Initiative
Brain Atrophy in Healthy Aging Is Related to CSF Levels of A{beta}1-42
Cereb Cortex,
January 4, 2010;
(2010)
bhp279v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Hu, S. L. Crick, G. Bu, C. Frieden, R. V. Pappu, and J.-M. Lee
Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide
PNAS,
December 1, 2009;
106(48):
20324 - 20329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D.C. Goos, M.I. Kester, F. Barkhof, M. Klein, M. A. Blankenstein, P. Scheltens, and W. M. van der Flier
Patients With Alzheimer Disease With Multiple Microbleeds: Relation With Cerebrospinal Fluid Biomarkers and Cognition
Stroke,
November 1, 2009;
40(11):
3455 - 3460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Vemuri, H. J. Wiste, S. D. Weigand, L. M. Shaw, J. Q. Trojanowski, M. W. Weiner, D. S. Knopman, R. C. Petersen, C. R. Jack Jr, and On behalf of the Alzheimer's Disease Neuroimaging
MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change
Neurology,
July 28, 2009;
73(4):
294 - 301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tapiola, I. Alafuzoff, S.-K. Herukka, L. Parkkinen, P. Hartikainen, H. Soininen, and T. Pirttila
Cerebrospinal Fluid {beta}-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Arch Neurol,
March 1, 2009;
66(3):
382 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Zetterberg, U. Andreasson, O. Hansson, G. Wu, S. Sankaranarayanan, M. E. Andersson, P. Buchhave, E. Londos, R. M. Umek, L. Minthon, et al.
Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease
Arch Neurol,
August 1, 2008;
65(8):
1102 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bian, J. C. Van Swieten, S. Leight, L. Massimo, E. Wood, M. Forman, P. Moore, I. de Koning, C. M. Clark, S. Rosso, et al.
CSF biomarkers in frontotemporal lobar degeneration with known pathology
Neurology,
May 6, 2008;
70(19_Part_2):
1827 - 1835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ewers, Z. Zhong, K. Burger, A. Wallin, K. Blennow, S. J. Teipel, Y. Shen, and H. Hampel
Increased CSF-BACE 1 activity is associated with ApoE-{varepsilon}4 genotype in subjects with mild cognitive impairment and Alzheimer's disease
Brain,
May 1, 2008;
131(5):
1252 - 1258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Engelborghs, K. Sleegers, P. Cras, N. Brouwers, S. Serneels, E. De Leenheir, J.-J. Martin, E. Vanmechelen, C. Van Broeckhoven, and P. P. De Deyn
No association of CSF biomarkers with APOE{varepsilon}4, plaque and tangle burden in definite Alzheimer's disease
Brain,
September 1, 2007;
130(9):
2320 - 2326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R Gustafson, I. Skoog, L. Rosengren, H. Zetterberg, and K. Blennow
Cerebrospinal fluid {beta}-amyloid 1-42 concentration may predict cognitive decline in older women
J. Neurol. Neurosurg. Psychiatry,
May 1, 2007;
78(5):
461 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Buerger, M. Ewers, T. Pirttila, R. Zinkowski, I. Alafuzoff, S. J. Teipel, J. DeBernardis, D. Kerkman, C. McCulloch, H. Soininen, et al.
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
Brain,
November 1, 2006;
129(11):
3035 - 3041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Stenset, L. Johnsen, D. Kocot, A. Negaard, A. Skinningsrud, P. Gulbrandsen, A. Wallin, and T. Fladby
Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42.
Neurology,
September 12, 2006;
67(5):
830 - 833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Peskind, G. Li, J. Shofer, J. F. Quinn, J. A. Kaye, C. M. Clark, M. R. Farlow, C. DeCarli, M. A. Raskind, G. D. Schellenberg, et al.
Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid beta-Amyloid 42 in Adults With Normal Cognition.
Arch Neurol,
July 1, 2006;
63(7):
936 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. M. Olde Rikkert, W. M. van der Flier, F. E. deLeeuw, M. Verbeek, R. W. M. M. Jansen, F. Verhey, and P. Scheltens
Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia
Arch Neurol,
January 1, 2006;
63(1):
144 - 146.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W M van der Flier and P Scheltens
Use of laboratory and imaging investigations in dementia
J. Neurol. Neurosurg. Psychiatry,
December 1, 2005;
76(suppl_5):
v45 - v52.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Moonis, J. M. Swearer, M. P. E. Dayaw, P. St. George-Hyslop, E. Rogaeva, T. Kawarai, and D. A. Pollen
Familial Alzheimer disease: Decreases in CSF A{beta}42 levels precede cognitive decline
Neurology,
July 26, 2005;
65(2):
323 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
